Wolchko Scott J.'s most recent trade in Fate Therapeutics Inc was a trade of 500,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | J. Wolchko Scott | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Wolchko Scott J. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.37 per share. | 09 Jan 2024 | 14,391 | 371,248 (0%) | 0% | 4.4 | 62,889 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 5.24 per share. | 10 Jan 2023 | 45,907 | 385,639 (0%) | 0% | 5.2 | 240,553 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.70 per share. | 21 Jul 2022 | 30,000 | 461,546 (0%) | 0% | 2.7 | 81,000 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2022 | 30,000 | 6,246 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 33.07 per share. | 21 Jul 2022 | 19,171 | 431,546 (0%) | 0% | 33.1 | 633,985 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.54 per share. | 21 Jul 2022 | 10,829 | 450,717 (0%) | 0% | 32.5 | 352,376 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2022 | 6,246 | 0 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.70 per share. | 21 Jul 2022 | 6,246 | 437,792 (0%) | 0% | 2.7 | 16,864 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 31.33 per share. | 21 Jul 2022 | 2,923 | 434,869 (0%) | 0% | 31.3 | 91,578 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.61 per share. | 21 Jul 2022 | 2,703 | 432,166 (0%) | 0% | 32.6 | 88,145 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 33.28 per share. | 21 Jul 2022 | 620 | 431,546 (0%) | 0% | 33.3 | 20,634 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.70 per share. | 21 Apr 2022 | 30,000 | 461,546 (0%) | 0% | 2.7 | 81,000 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2022 | 30,000 | 46,246 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.57 per share. | 21 Apr 2022 | 22,715 | 438,831 (0%) | 0% | 34.6 | 785,258 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.70 per share. | 21 Apr 2022 | 10,000 | 441,546 (0%) | 0% | 2.7 | 27,000 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2022 | 10,000 | 36,246 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.54 per share. | 21 Apr 2022 | 9,162 | 432,384 (0%) | 0% | 34.5 | 316,455 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.73 per share. | 21 Apr 2022 | 4,062 | 434,769 (0%) | 0% | 35.7 | 145,135 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 36.70 per share. | 21 Apr 2022 | 2,220 | 432,549 (0%) | 0% | 36.7 | 81,474 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 37.90 per share. | 21 Apr 2022 | 1,003 | 431,546 (0%) | 0% | 37.9 | 38,014 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.15 per share. | 21 Apr 2022 | 838 | 431,546 (0%) | 0% | 35.2 | 29,456 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 289,403 | 289,403 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.70 per share. | 20 Jan 2022 | 30,000 | 461,546 (0%) | 0% | 2.7 | 81,000 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2022 | 30,000 | 86,246 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2022 | 10,000 | 76,246 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 48.50 per share. | 11 Jan 2022 | 10,047 | 436,065 (0%) | 0% | 48.5 | 487,280 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 49.07 per share. | 11 Jan 2022 | 4,519 | 431,546 (0%) | 0% | 49.1 | 221,747 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 47.17 per share. | 10 Jan 2022 | 20,894 | 446,213 (0%) | 0% | 47.2 | 985,570 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 46.36 per share. | 10 Jan 2022 | 13,161 | 467,107 (0%) | 0% | 46.4 | 610,144 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 47.72 per share. | 10 Jan 2022 | 101 | 446,112 (0%) | 0% | 47.7 | 4,820 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 86,475 | 480,268 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 54.27 per share. | 18 Nov 2021 | 20,000 | 393,793 (0%) | 0% | 54.3 | 1,085,400 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.70 per share. | 18 Nov 2021 | 20,000 | 413,793 (0%) | 0% | 2.7 | 54,000 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2021 | 20,000 | 79,446 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2021 | 30,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 58.88 per share. | 21 Oct 2021 | 30,000 | 393,793 (0%) | 0% | 58.9 | 1,766,400 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.73 per share. | 21 Oct 2021 | 30,000 | 423,793 (0%) | 0% | 2.7 | 81,900 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 59.82 per share. | 21 Oct 2021 | 15,235 | 408,558 (0%) | 0% | 59.8 | 911,358 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2021 | 15,154 | 99,446 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.70 per share. | 21 Oct 2021 | 15,154 | 423,793 (0%) | 0% | 2.7 | 40,916 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 60.63 per share. | 21 Oct 2021 | 14,765 | 393,793 (0%) | 0% | 60.6 | 895,202 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2021 | 10,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.73 per share. | 21 Oct 2021 | 10,000 | 403,793 (0%) | 0% | 2.7 | 27,300 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.84 per share. | 21 Oct 2021 | 4,846 | 408,639 (0%) | 0% | 4.8 | 23,455 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2021 | 4,846 | 0 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 20,000 | 4,846 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.84 per share. | 19 Aug 2021 | 20,000 | 413,793 (0%) | 0% | 4.8 | 96,700 | Common Stock |
| Fate Therapeutics Inc | J. Scott Wolchko | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 88.01 per share. | 19 Aug 2021 | 20,000 | 393,793 (0%) | 0% | 88.0 | 1,760,204 | Common Stock |